
Cerecor Inc. Revenue 2011-2026 | CERC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Cerecor Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 6.7 M | 6.75 M | 18.3 M | 27.8 M | 1.15 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.8 M | 1.15 M | 12.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
463 M | $ 9.33 | 1.41 % | $ 603 M | ||
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
88 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
912 K | $ 0.87 | -2.13 % | $ 6.4 M | ||
|
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
958 M | $ 22.38 | 0.81 % | $ 3.71 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
Galapagos NV
GLPG
|
1.11 B | $ 28.15 | 1.04 % | $ 2.69 B | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Grifols, S.A.
GRFS
|
7.21 B | $ 8.22 | 3.92 % | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
868 M | $ 30.95 | -0.34 % | $ 1.78 B | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
ImmuCell Corporation
ICCC
|
27.6 M | $ 8.43 | -0.12 % | $ 76.1 M | ||
|
InflaRx N.V.
IFRX
|
29.3 K | $ 1.97 | -0.51 % | $ 152 M | ||
|
Incyte Corporation
INCY
|
5.14 B | $ 98.55 | -0.55 % | $ 19.2 B | ||
|
InMed Pharmaceuticals
INM
|
4.14 M | $ 0.71 | 1.27 % | $ 1.74 M | ||
|
Innoviva
INVA
|
411 M | $ 22.97 | -0.35 % | $ 1.55 B | ||
|
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
482 M | $ 104.02 | 2.41 % | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
Jaguar Health
JAGX
|
11.5 M | $ 7.34 | -6.79 % | $ 17.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | ||
|
KalVista Pharmaceuticals
KALV
|
49.1 M | $ 26.68 | 0.02 % | $ 1.44 B | ||
|
Innate Pharma S.A.
IPHA
|
9 M | $ 1.45 | -2.68 % | $ 235 M | ||
|
Kamada Ltd.
KMDA
|
180 M | $ 8.16 | 0.68 % | $ 260 M | ||
|
Krystal Biotech
KRYS
|
389 M | $ 260.24 | 0.11 % | $ 7.53 B | ||
|
Kazia Therapeutics Limited
KZIA
|
1.07 M | $ 13.58 | 9.34 % | $ 1.8 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
167 M | $ 220.06 | -2.13 % | $ 4.02 B | ||
|
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 2.94 | -1.67 % | $ 4.84 M | ||
|
Liquidia Corporation
LQDA
|
158 M | $ 38.41 | 0.67 % | $ 3.31 B | ||
|
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | ||
|
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | ||
|
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.08 | 0.62 % | $ 436 M | ||
|
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
3.09 M | - | 17.91 % | $ 11.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
376 M | $ 23.15 | 3.49 % | $ 2.95 B |